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Abstract
 
Professional antigen-presenting cells (APCs) are capable of transporting self-antigens from pe-
ripheral tissues to secondary lymphoid organs where they are presented to potentially autoreac-
tive CD8
 
 
 
 T cells. In the absence of an inflammatory response, this results in immune toler-
ance. The presence of activated, antigen-specific CD4
 
 
 
 T cells converts this tolerogenic
encounter into an immunogenic one by promoting extensive proliferation of CD8
 
 
 
 T cells
and their development into effectors. Surprisingly, activation of APCs with an agonistic anti-
body specific for CD40 could not substitute for CD4
 
 
 
 help in this task. Anti-CD40 induced
recruitment of dendritic cells expressing high levels of B7 costimulatory molecules into the
lymph nodes, which in turn, greatly enhanced activation and expansion of CD8
 
 
 
 T cells.
However, these activated CD8
 
 
 
 cells did not demonstrate effector function. We conclude that
proliferative potential and gain of effector function are separable events in the differentiation
program of CD8
 
 
 
 T cells.
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Introduction
 
Not all potentially autoreactive T cells are deleted during
thymic development and therefore, peripheral mechanisms
of tolerance also exist to help prevent autoimmunity. Dele-
tion and anergy of potentially autoreactive CD8
 
 
 
 T cells in
the periphery has been demonstrated to occur for both
 
self- and tumor antigens (1, 2). Dendritic cells (DCs)
 
*
 
 play
an important role in this process, as they are able to ac-
quire, process, and present antigens expressed by parenchy-
mal tissue and carry them to naive T cells transiting
through draining LNs (3–5). Such presentation of exoge-
nously acquired antigens by DCs is referred to as cross-pre-
sentation (6, 7). DCs also cross-present foreign antigens
and pathogens and support the proliferation and differenti-
ation of T cells into effectors (8, 9). The basis underlying
how DCs can be responsible for both tolerance and immu-
nity is still unclear. A variety of hypotheses have been pro-
posed to explain this dual function of DCs. One such theory
proposes that different subclasses of DCs are involved in
presentation of toleragen versus antigen (10, 11). Another
proposes it is the activation status of the DCs, which is de-
terminative of the outcome (12). DCs that have been acti-
vated, directly or indirectly, through pathogens or adju-
vants, convert from a tolerogenic to an immunogenic
source of antigen (12). Yet another possibility relates to the
different stages in the development of DCs. Immature DCs
have been proposed to be tolerogenic, whereas activated,
mature DCs could induce efficient CTL responses (13, 14).
Evaluation of these possibilities is further complicated by
evidence that DCs have the capacity to transfer antigen,
such that the DCs responsible for carrying self-antigen to
LNs may not be the same as those which present the same
antigen to T cells (4, 14).
The importance of CD4
 
 
 
 T cell help in promoting an
effective CD8
 
 
 
 T cell response is well established. Recent
studies suggest that the mechanism by which CD4
 
 
 
 cells
accomplish such ‘help’ is through activation of DCs by en-
gagement of CD40 (15–17). Such activation in vitro results
in enhanced expression of B7 costimulatory molecules and
production of inflammatory cytokines, such as IL-12,
which greatly augments CD8 responses (18, 19). In vivo,
CD40 activated DCs also have an increased migratory po-
tential toward secondary lymphoid organs, which would
result in the enhanced transport of antigen to the draining
LNs where they activate naive T cells (20). Engagement of
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CD40 by the in vivo administration of agonistic mAbs has
been shown to prevent peptide-induced tolerance of
CD8
 
 
 
 T cells (21, 22). Another way CD4
 
 
 
 cells assist
CD8
 
 
 
 T cells is by providing IL-2, and systemic injection
of IL-2 has been shown to reverse tumor-induced anergy
of CD8
 
 
 
 T cell (23).
Our laboratory has been studying peripheral tolerance of
CD8
 
 
 
 T cells in InsHA mice that express the hemaggluti-
nin (HA) protein from the influenza virus under the con-
trol of the rat insulin promoter (24). InsHA mice are toler-
ant of HA that is expressed on the 
 
 
 
 cells of the pancreatic
islets, such that the TCR repertoire is purged of T cells
with high avidity for HA (24–26). We have demonstrated
previously that HA specific CD8
 
 
 
 T cells can leave the
thymus and become tolerized in the periphery (24, 27). To
study the mechanism of tolerance induction in the periph-
ery, we have used clone 4 TCR transgenic mice that ex-
press a TCR receptor specific for the major K
 
d
 
 restricted
HA epitope (27). Upon transfer of naive clone 4 CD8
 
 
 
 T
cells into InsHA recipients, the T cells proliferate in the
draining LNs of the pancreas (28, 29). The proliferating
clone 4 CD8
 
 
 
 T cells display a distinctive phenotype that
distinguish them from either naive or effector cells (30).
They do not exhibit cytolytic activity or production of
IFN-
 
 
 
, both of which are key effector activities of CD8
 
 
 
 T
cells (30). The activated clone 4 T cells do not cause diabe-
tes or even insulitis and appear to die within the lymphoid
tissue (28–30). Since InsHA mice are also tolerant of HA in
the CD4
 
 
 
 compartment (24), we have investigated the
possibility of overcoming CD8
 
 
 
 T cell tolerance with an
exogenous source of antigen specific help in the form of
HA-specific CD4 cells from the HNT TCR transgenic line
or with an agonistic anti-CD40 mAb.
 
Materials and Methods
 
Mice.
 
BALB/c mice were purchased from the breeding col-
ony of The Scripps Research Institute. InsHA (24), clone 4 TCR
(27), HNT TCR (31), and DO11 (provided by Susan Webb,
The Scripps Research Institute; reference 35) transgenic mice
lines had been backcrossed with BALB/c mice for at least eight
generations. Clone 4 mice were then crossed with BALB/c
Thy1.1
 
 
 
/
 
 
 
 for two generations to achieve homozygosity for
Thy1.1. Mice were propagated and maintained under specific
pathogen-free conditions in The Scripps Research Institute’s ani-
mal facility. All mice used in these studies were between 8 and 12
wk of age. Experimental procedures were performed according
to the National Institutes of Health Guide for Care and Use of
Laboratory Animals.
 
Preparation of Naive TCR Transgenic T Cells.
 
CD8
 
 
 
 
 
Thy1.1
 
 
 
T cells from clone 4 TCR were prepared as described previously
(30). Briefly, single cell suspensions from spleen and LN of clone
4 TCR transgenic mice were sequentially subject to hypotonic
red blood cell lysis, B cell depletion in a nylon wool column and
mAb (clone RL172)-directed complement depletion of CD4
 
 
 
 T
cells. HNT and DO11 CD4
 
 
 
 T cells were prepared in a similar
way using anti-CD8 mAb (clone 3.155) for the complement de-
pletion of CD8
 
 
 
 T cells instead of CD4
 
 
 
 T cells. T cell purity
was 
 
 
 
80%.
 
CFSE Labeling.
 
Purified T cells, at a maximum concentra-
tion of 5 
 
 
 
 10
 
7
 
 cells/ml, were incubated in 5 
 
 
 
M CFSE (Molec-
ular Probes) in HBSS for 10 min at 37
 
 
 
C. Cells were then
washed with ice-cold HBSS.
 
In Vitro Activation of TCR Transgenic CD4
 
 
 
 T Cells.
 
Purified
HNT or DO11 CD4
 
 
 
 T cells were seeded in 24-well plates, 2 
 
 
 
10
 
6
 
 per well, in RPMI 1640 media containing 10% FBS, 2 mM
glutamine, 5 
 
 
 
 10
 
 
 
5
 
 M 
 
 
 
-mercaptoethanol, and 50 
 
 
 
g/ml gen-
tamicin sulfate (complete media). For the priming of HNT cells,
BALB/c spleen cells infected with influenza virus A/PR/8/34
H1N1 that was grown in the allantoic cavity of 10-d-old hen’s
eggs were used as APC. Cells from one spleen were irradiated
(3,000 rads), mixed with 500 HA units of virus in 1 ml of serum
free media and incubated at 37
 
 
 
C for 1 h. After washing, 6 
 
 
 
 10
 
6
 
cells per well were added to the cultures containing HNT cells.
For the priming of DO11 cells, irradiated BALB/c spleen cells
that had been pulsed for 2 h at 37
 
 
 
C with 1 
 
 
 
g/ml of OVA 323–
339 peptide in complete media were used as APCs. In some ex-
periments several wells were seeded with CFSE-labeled CD4
 
 
 
 T
cells. Cultures were maintained at 37
 
 
 
C for 3 d and then viable
cells were isolated by Ficoll-Paque separation.
 
Adoptive Transfer.
 
Recipient InsHA mice were injected intra-
venously with either 3 
 
 
 
 10
 
6
 
 CFSE-labeled clone 4 TCR Thy
1.1
 
 
 
/
 
 
 
 CD8
 
 
 
 T cells or 3 
 
 
 
 10
 
6
 
 CFSE-labeled HNT TCR
CD4
 
 
 
 T cells in 200 
 
 
 
l of HBSS on day 0. In certain experi-
ments, immediately after transfer, groups of mice were immu-
nized intraperitoneally with 500 HA units of influenza virus. In
other experiments, mice were coinjected with 3 
 
 
 
 10
 
6
 
 CFSE-
labeled clone 4 TCR Thy 1.1
 
 
 
/
 
 
 
 CD8
 
 
 
 T cells and 3 
 
 
 
 10
 
6
 
nonlabeled HNT TCR CD4
 
 
 
 T cells, 1.5 
 
 
 
 10
 
6
 
 nonlabeled, in
vitro–activated HNT CD4
 
 
 
 T cells or 1.5 
 
 
 
 10
 
6
 
 nonlabeled, in
vitro–activated DO11 CD4
 
 
 
 T cells.
 
Ab and Cytokine Treatment.
 
InsHA mice that received CFSE-
labeled clone 4 T cells were injected intravenously on day 0 with
150 
 
 
 
g of the agonistic anti-CD40 mAb FGK45 (a gift from
Stephen Schoenberger, La Jolla Institute for Allergy and Immu-
nology, La Jolla, CA) in 200 
 
 
 
l of HBSS. Control mice received
150 
 
 
 
g purified rat IgG (Jackson ImmunoResearch Laboratory).
Mice from these two groups where split and half of them re-
ceived 5,000 U of recombinant human IL-2 (obtained from the
National Cancer Institutes) intraperitoneally on days 1–3 in 200
 
 
 
l of HBSS. Groups of mice that were killed on day 20 after cell
transfer received Abs on days 0, 5, and 10 and IL-2 on days 1, 2,
3, 7, 8, 12, and 13. Alternatively, a single dose of 1 
 
 
 
g of IL-12 (a
gift from Stanley Wolf, The Genetics Institute, Andover, MA)
was administered intraperitoneal on day 1. Attempts to provide
additional doses of IL-12 were hampered by increased morbidity.
In some experiments mice were treated with a combination of
purified anti-B7.1 (clone 16–10A1; American Type Culture Col-
lection) plus anti-B7.2 (clone GL1; ATCC) mAbs; 100 
 
 
 
g of
each Ab per mouse per dose. Groups of mice treated with puri-
fied hamster IgG plus rat IgG (Jackson ImmunoResearch Labora-
tories) served as isotype controls. Abs were administered intra-
peritoneal in HBSS on days 0–3, and on day 5 in groups of mice
killed on day 8.
 
Diabetes Monitoring.
 
Mice were monitored for diabetes by
measuring blood glucose on days 4, 6, 8, and every 4 d thereafter
for mice that were killed on day 20. They were considered dia-
betic when glucose levels were above 300 mg/dl.
 
Flow Cytometry.
 
4 or 8 d after adoptive transfer, pancreatic
LNs, and a mixture of other LNs including inguinal, axillary,
cervical, and mandibular were excised and processed separately
to obtain single cell suspensions. After counting, all the cells 
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from the pancreatic LNs and an equivalent number of cells from
the other LNs were stained with the indicated Abs. LNs from
three mice receiving the same treatment were pooled together
for staining.
All mAbs and secondary reagents were purchased from BD
PharMingen. Donor clone 4 T cells were detected and enumer-
ated by virtue of their Thy1.1 expression. LN cells were incu-
bated with anti-CD8
 
 
 
-PerCP and anti-Thy1.1-PE mAbs in
HBSS, 0.1% BSA, 0.02% sodium azide for 30 min at 4
 
 
 
C. After
washing, cells were analyzed with a FACSCalibur™ apparatus
using CELLQuest™ software (BD Biosciences). In analyzing
each sample, 1.5 
 
 
 
 10
 
6
 
 events were collected.
For clone 4 CD8
 
 
 
 T cells, the intensity of CFSE fluorescence
was analyzed in the CD8
 
 
 
 Thy1.1
 
 
 
 subpopulation of lympho-
cytes on day 4 after transfer. For HNT cells this was performed
gating on CD4
 
 
 
 T cells after staining the LN cells with anti–
CD4-PE mAb. CFSE fluorescence analyses on in vitro cultured
CD4
 
 
 
 T cells were performed by propidium iodide exclusion of
dead cells and gating on CD4
 
 
 
 T cells.
To assess production of IFN-
 
 
 
 in response to antigen, LN cells
were incubated in complete media with 1 
 
 
 
g/ml of the K
 
d
 
 HA
peptide (IYSTVASSL) and 1 
 
 
 
l/ml of brefeldin A containing
Golgi-Plug solution (BD PharMingen) for 6 h at 37
 
 
 
C. An irrele-
vant peptide was used instead of the K
 
d
 
 HA peptide as a negative
control. After washing, cells were stained to detect cell surface
CD8 and Thy1.1 as described above. Cells were then permeabi-
lized and stained to detect intracellular IFN-
 
 
 
 with anti–IFN-
 
 
 
-
APC mAb using the Cytofix/Cytoperm Plus kit (BD PharMin-
gen) according to manufacturer’s instructions.
For the detection and analysis of the activation status of DCs,
single cell suspensions of pancreatic LNs on day 4 after treatment
were stained with an anti–CD11c-FITC mAb plus anti–B7.1-
PE or B7.2-PE for 20 min at 4
 
 
 
C. 10
 
5
 
 events were collected in
these experiments.
 
Immunohistochemisty.
 
Pancreas were excised on day 8 after
transfer, fixed in a 10% formalin solution (Sigma-Aldrich), and
processed for paraffin embedding. Serial sections were immuno-
stained for the detection of insulin or stained with eosin (Sigma-
Aldrich) as described previously (28). Finally slides, were coun-
terstained with Mayer’s Hematoxylin (Sigma-Aldrich).
 
Results
 
CD4 Help Prevents CD8
 
 
 
 T Cell Tolerance Induction.
 
HNT TCR transgenic mice express a TCR specific for an
I-A
 
d
 
–restricted epitope of the HA protein on CD4
 
 
 
 T cells
(31). When labeled with CFSE and injected into InsHA
mice, naive HNT CD4
 
 
 
 T cells behave much the same as
HA-specific naive Clone 4 CD8
 
  T cells in this same situ-
ation (29). Small numbers of these cells become activated
and proliferate in the pancreatic LNs but not elsewhere in
the host (Fig. 1 A). Furthermore, these adoptively trans-
ferred HNT CD4  T cells do not spontaneously induce di-
abetes (Table I).
We next coinjected clone 4 CD8  T cells and HNT
CD4  T cells into InsHA recipients and monitored prolif-
eration of the CFSE-labeled clone 4 CD8  cells in the
pancreatic LNs. The proliferation profile did not differ
from that observed when Clone 4 CD8  T cells were
transferred alone (Fig. 2 A). Initially, the total numbers of
clone 4 CD8  T cells recovered from the pancreatic LNs
was not substantially different from the control which did
not receive HNT cells (Fig. 2 B). However, at a later time
point, day 8, a slight increase was noticeable in these num-
bers of clone 4 CD8  T cells recovered, relative to the
mice injected with clone 4 CD8  T cells alone (Fig. 2 B).
No infiltrates were observed in the pancreatic islets on day
8 (Table I). Also, blood glucose levels remained normal,
even in mice that were monitored for 3 wk after cotrans-
fer (Table I). This demonstrates that in the conditions
used in this experiment, HA-specific CD4  T cells acti-
vated by cross-presented self-antigen are unable to cause
diabetes, nor can they promote diabetes by HA-specific
CD8  cells.
This finding was somewhat surprising, as there have
been a number of reports demonstrating that CD4  cells
prevent tolerance and promote a vigorous immune re-
sponse by CD8  cells (32–34). However, in the HA
model, very few CD4  and CD8  cells become activated
at any given time, due to the limiting amount of cross-pre-
sented antigen. To determine if larger numbers of activated
CD4  cells could prevent tolerance of the clone 4 CD8  T
cells specific for HA, we coinjected naive clone 4 CD8  T
cells along with HNT CD4  T cells that were previously
activated in vitro with influenza virus (Fig. 1 B). A dra-
matic expansion of CSFE-labeled clone 4 CD8   T cells
Figure 1. In vivo and in vitro proliferation of HNT CD4  T cells. (A)
3   106 CFSE-labeled, purified, Thy1.1  clone 4 CD8  T cells (top) or
HNT CD4  T cells (bottom) were injected into InsHA hosts. Mice were
killed on day 4 after transfer and cells from LNs were analyzed by FACS®.
Histograms represent the amount of CFSE label gating on CD8  Thy1.1 
lymphocytes (top) or CD4  lymphocytes (bottom) of one representative
experiment of five independent ones for clone 4 and three for HNT. The
unstained cells in the bottom panels represent the endogenous CD4  T
cell repertoire. (B) Purified, CFSE-labeled HNT or DO11 CD4  T cells
were activated in vitro for 3 d and analyzed by FACS®. Histograms repre-
sent the amount of CFSE label gating on live CD4  T cells.326 Uncoupling Proliferation and Effector Function in CD8  T Cells
was detected in the pancreatic LNs of the InsHA recipients
receiving both the activated HNT CD4  cells and the na-
ive clone 4 CD8  cells (Fig. 2 A). This was evident in both
the proliferation profiles and in the total number of cells re-
covered from pancreatic LNs (Fig. 2 B). The majority of
recipients (88%) became diabetic by day 8 after transfer
(Table I). Immunohistological analysis of the pancreas
showed massive infiltration of the islets and destruction of
the   cells (Table I). Mice that received the same number
of in vitro activated HNT cells alone, without receiving
clone 4 CD8  cells did not become diabetic (Table I).
However, these cells did migrate into the pancreas, locating
mainly in the periphery of the islets (Table I).
To determine if the CD4  cells had to be specific for the
islet antigen in order to promote activation of clone 4
CD8  cells, CD4  T cells from DO11 TCR transgenic
mice, which express a TCR specific for an I-Ad–restricted
OVA peptide (35), were activated in vitro (Fig. 1 B) and
coinjected with clone 4 CD8  T cells. No enhancement of
proliferation or accumulation of clone 4 CD8  T cells was
observed (Fig. 2, A and B), suggesting a requirement for
interaction between the activated CD4  cells and the HA-
presenting DCs in order to enhance the response by clone
4 CD8  T cells.
We previously demonstrated that clone 4 CD8  T cells
proliferating in the pancreatic LNs of InsHA mice do not
develop effector functions, such as production of IFN- 
(Fig. 2 C) and cytolytic activity (30). The experiments de-
scribed above imply that the presence of activated HNT
CD4  cells not only enhanced activation of the naive clone
4 T cells, but also promoted effector function. To directly
assess this issue, we monitored the ability of in vivo acti-
vated clone 4 T cells to produce IFN- . Clone 4 CD8  T
cells proliferating after coinjection with naive HNT pro-
duced little IFN-  (Fig. 2 C). In contrast, a high propor-
tion of the clone 4 CD8  T cells that proliferated in the
presence of activated HNT were able to efficiently produce
IFN- . 42% of the clone 4 CD8  T cells in the pancreatic
LNs were IFN-   after a brief period of activation in vitro
with HA peptide (Fig. 2 C). This is almost comparable to
the percentage of clone 4 CD8  T cells producing IFN- 
when they are activated by priming in vivo with influenza
virus (Fig. 2 C). These results indicate that activated HA-
specific HNT CD4  cells can promote vigorous prolifera-
tion of clone 4 CD8  T cells and their differentiation into
effector cells.
Comparison of the Effects of Anti-CD40 and CD4 Help on
Clone 4 CD8  T Cells. CD4  T cells promote activation
and proliferation of CD8  cells indirectly, through the ac-
tivation of DCs by CD40-CD40L interaction, and also di-
rectly, by providing IL-2. To better understand the mecha-
nisms by which activated HNT CD4  cells prevent
deletion of clone 4 CD8  T cells in the pancreatic LNs, we
examined separately the contribution of IL-2 and activation
of DCs through CD40. 
Systemic administration of IL-2 in InsHA mice that had
received clone 4 CD8  T cells induced a slight increase in
the total numbers of these cells in the pancreatic LNs com-
Table I. Diabetes Incidence in InsHA Mice
Islet infiltrationa
Adoptive transfer and treatment  Clear Periinsulitis Insulitis Islet destruction Diabetes incidenceb
(%) (%) (%) (%) (%)
Clone 4 n   33 100 0 0 0 n   21 0
Clone 4 plus HNTc n   27 93 7 0 0 n   11 0
Clone 4 CD8+ plus activated DO11 n   18 89 11 0 0 n   60
Clone 4 CD8+ plus activated HNT n   30 0 10 90 100 n   98 8
Clone 4 plus activated HNT plus anti-B7.1
plus B7.2 n   23 44 44 8 13 n   60
Clone 4 plus IL-2c n   22 96 4 0 0 n   80
Clone 4 plus anti-CD40c n   31 97 3 0 0 n   11 0
Clone 4 plus anti-CD40 plus IL-2c n   24 96 4 0 0 n   90
Clone 4 plus anti-CD40 plus IL-12 n   36 45 55 0 0 ND
Activated HNTc n   26 8 77 15 14 n   90
HNTc ND ND ND ND n   60
Groups of InsHA mice were treated as indicated and monitored for diabetes for 8 or 20 d. Mice were considered diabetic when the blood glucose
levels were  300 mg/dl. Pancreas from mice sacrificed on day 8 were subject to histological analysis to determine the presence of islet infiltrates. Islet
destruction was determined by the absence of insulin staining. ND, nondetermined.
aTotal numbers of islets examined in each group is indicated. Pancreatic sections from two to four mice per group were analyzed, except in the
group that received clone 4 plus anti-CD40 plus IL-12 in which sections from seven mice were studied.
bTotal number of mice monitored for diabetes per group is indicated.
cConditions for which a group of three mice was monitored for 20 d.327 Hernández et al.
pared with mice that received Clone 4 CD8  T cells alone
(Fig. 3, A and B). However, mice did not become diabetic
and no infiltrates were found after histological examination
of the pancreatic islets (Table I).
Agonistic FGK45 anti-CD40 mAb has been shown to
replace CD4  T cell help in the development of CD8  T
cell responses (15–17). Consistent with these reports, we
found that injection of this mAb into InsHA mice receiv-
ing clone 4 CD8  T cells resulted in a dramatic enhance-
ment of proliferation of these cells in the pancreatic LNs as
compared with mice that received clone 4 CD8  T cells
and an isotype matched control Ab (Fig. 3). We observed a
sixfold increase in the total numbers of clone 4 CD8  T
cells in the pancreatic LNs as compared with controls (Fig.
3 B). Surprisingly, none of the mice analyzed developed di-
abetes at day 8 (Table I). Mice that received serial injec-
tions of the agonistic mAb every five days were monitored
for 3 wk and were found to display normal blood glucose
levels. At this late time point almost all the clone 4 CD8 
T cells have disappeared from the lymphoid organs (un-
published data). A combined treatment with anti-CD40
mAb and IL-2 produced results similar to those obtained
with anti-CD40 alone (Fig. 3, A and B and Table I).
Again, only a slight increase in the total numbers of clone 4
CD8  T cells was seen, as compared with mice that re-
ceived anti-CD40 alone.
To rule out the possibility that the enhanced prolifera-
tion of HA-specific CD8  T cells observed in InsHA hosts
given anti-CD40 mAb is simply due to enhanced homeo-
static division promoted by a generalized activation of
DCs, we analyzed the proliferative potential of clone 4
cells in an antigen free environment. We had previously
shown that clone 4 cells transferred into nonirradiated
BALB/c recipients, where antigen is not present, do not
proliferate (30). Clone 4 cells transferred into BALB/c
mice that received anti-CD40 mAb did not undergo pro-
liferation (Fig. 3, A bottom) indicating that the enhanced
proliferation induced by anti-CD40 treatment is antigen
dependent. 
The surprising result that anti-CD40 resulted in massive
proliferation yet did not promote development of diabetes,
lead us to question whether the cells had acquired effector
activity and whether they migrated to the pancreas. To de-
termine if clone 4 CD8  T cells responding to cross-pre-
sented self-antigen in the presence of anti-CD40 mAb de-
veloped into effectors, we tested their ability to secrete
IFN- . Surprisingly, very few of the cells retrieved from
the pancreatic LNs of anti-CD40–treated mice were able
to efficiently produce IFN-  (Fig. 3 C). When stimulated
briefly in vitro with HA peptide, only 11% were IFN-  .
This represents less than a threefold increase over the clone
4 CD8  T cells injected alone in contrast to the 10-fold
Figure 2. Activated HNT
CD4  T cells enhance prolifera-
tion and effector function of
clone 4 CD8  T cells in the pan-
creatic LNs of InsHA mice. 3  
106 CFSE-labeled, purified,
Thy1.1  clone 4 CD8  T cells
were injected into InsHA hosts
either alone or along with nonla-
beled, 3   106 purified HNT
CD4  T cells, 1.5   106 in vitro
activated HNT CD4  T cells or
1.5    106 in vitro activated
DO11 CD4  T cells, as indi-
cated. These data is representa-
tive of two to five independent
experiments including a total of
at least six mice per group per
time point. (A) Mice were killed
on day 4 after transfer and cells
from pancreatic LNs were ana-
lyzed by FACS®. Histograms
represent the amount of CFSE
label gating on CD8  Thy1.1 
lymphocytes. (B) Total numbers
of CD8  Thy1.1  cells in the
pancreatic LNs of host mice
killed on days 4 and 8 after trans-
fer. Data represent the mean of
all experiments performed. Only
negative standard deviation is de-
picted to achieve greater sensi-
tivity in the graph. (C) On day 4
after transfer cells from pancre-
atic LNs were incubated with Kd HA peptide for 6 h and then analyzed by FACS® to detect accumulation of intracellular IFN- . Plots represent the
amount of CFSE label versus the intensity of IFN-  produced gating on lymphocytes CD8  Thy1.1 . The percentage of clone 4 IFN-   cells is indi-
cated. The percentage of IFN-   cells in controls that were stimulated with an irrelevant peptide was  1% in all the cases.328 Uncoupling Proliferation and Effector Function in CD8  T Cells
increase observed in the clone 4 CD8  T cells coinjected
with activated HNT cells (Fig. 2 C). To confirm the com-
promised functionality of these cells their cytolytic activity
was assessed and very little if any was found (unpublished
data) Furthermore, histological examination revealed that
very few of the anti-CD40 activated cells could be found
in the islets (Table I), despite the fact that by day 20 most
of these cells had left the pancreatic LNs. These results in-
dicate that enhancement of proliferative potential did not
necessarily result in the development of effector functions
by the clone 4 T cells and that anti-CD40 treatment could
not replace activated HNT helpers in promoting the dif-
ferentiation of clone 4 CD8  T cells into effectors.
B7 Costimulation Is Required for Accumulation of Large
Numbers of Activated Clone 4 CD8  T Cells and for Induction
of Diabetes. We previously reported that clone 4 CD8  T
cells undergoing proliferation and tolerance in response to
HA cross-presented in the pancreatic LNs did not require
costimulation through CD28 (30). We wished to deter-
mine whether B7 was involved in the proliferation ob-
served in response to anti-CD40 or activated HNT CD4 
cells and in the generation of clone 4 effector cells in the
presence of activated HNT cells. InsHA mice that received
a mixture of either naive clone 4 CD8  cells and activated
HNT CD4  cells, or clone 4 CD8  cells and anti-CD40
were also given anti-B7.1 plus anti-B7.2 mAbs to block
CD28 costimulation. In both conditions, the antibodies
were found to severely inhibit accumulation of clone 4
CD8  T cells in the pancreatic LNs of InsHA mice (Fig. 4
A). Also, the number of IFN- –producing cells induced
by the presence of activated HNT CD4  cells was dimin-
ished threefold (compare Figs. 2 D and 4 B). Most impor-
tantly, the anti-B7 mAbs protected mice that received the
mixture of activated HNT cells and naive clone 4 CD8 
cells from developing diabetes (Table I). Therefore, en-
gagement of CD28 on clone 4 T cells is necessary for their
accumulation in large numbers and also their differentia-
tion into effectors.
CD40 cross-linking has been shown to upregulate B7
expression on DCs and to promote their migration from
the parenchyma to lymphoid tissue (20, 36, 37). A number
of reports have implicated these cells as the ones responsible
for cross-presentation of antigen (3, 5, 38). In fact, InsHA
mice treated with anti-CD40 mAb showed a sixfold in-
crease in the numbers of CD11c  cells in the pancreatic
LN (Fig. 5 A). Also, the expression of B7.1 and B7.2 was
Figure 3. Anti-CD40 treatment enhances
proliferation but not effector function of
clone 4 CD8  T cells in the pancreatic LNs
of InsHA mice. 3   106 CFSE-labeled, pu-
rified, Thy1.1  clone 4 CD8  T cells were
injected into InsHA or BALB/c hosts. Mice
were then treated with anti-CD40 mAb or
purified rat IgG as isotype control. Anti-
CD40 treated mice and isotype controls
were then either left without further treat-
ment or treated with IL-2 or IL-12 as de-
scribed in Materials and Methods and as in-
dicated in the figure. These data is
representative of two to five independent
experiments including a total of at least six
mice per group per time point. (A) Prolifer-
ation profiles of clone 4 CD8  T cells on
day 4 after transfer were determined as in
Fig. 2 A. (B) Total numbers of CD8 
Thy1.1  cells in the pancreatic LNs of host
mice killed on days 4 or 8 after transfer de-
termined as in Fig. 2 B. (C) Production of
IFN-  on day 4 after transfer was deter-
mined as in Fig. 2 C.329 Hernández et al.
upregulated on these cells (Fig. 5 B). These results suggest
that enhanced proliferation induced by anti-CD40 treat-
ment is attributable to both the availability of more antigen
and the upregulation of B7 costimulatory molecules. How-
ever, as the clone 4 CD8  T cells did not develop effector
function when stimulated in the presence of anti-CD40,
the results indicate that B7 costimulation is necessary for
optimal accumulation of activated Clone 4 CD8  T cells,
but it is not sufficient for their development into effectors.
IL-12 Can Trigger Effector Function in Activated CD8  T
Cells. The results described above indicate that CD40 en-
gagement is able to result in enhanced proliferation and ac-
cumulation of CD8  T cells, but this does not promote de-
velopment of effector function. One of the most potent
signals for development of effector function by CD8  cells
is IL-12 (39). Therefore, we wished to determine if the
clone 4 CD8  T cells could develop effector activity when
provided both anti-CD40 and IL-12. Recipients that re-
ceived IL-12 and anti-CD40 along with the naive clone 4
CD8  T cells showed a threefold increase in the propor-
tion of activated CD8  T cells that could produce IFN- 
respect to anti-CD40 alone (Fig. 3 C). Examination of the
pancreas from these mice showed also a slight increase in
the number of islets infiltrated (Table I). IL-12 alone was
also able to enhance proliferation of clone 4 cells (Fig. 3 A).
However, in the absence of CD40 engagement, IL-12
alone was not able to promote IFN-  production by clone
4 CD8  T cells (Fig. 3 C).
Discussion
One important function of DCs is the cross-presenta-
tion of antigens expressed in the parenchyma to naive T
cells in secondary lymphoid tissue. This provides a mecha-
nism by which potentially autoreactive CD8  T cells that
escape thymic deletion may be purged from the repertoire
(2). This tolerance mechanism appears to be most useful in
situations in which peripheral antigens are either not ex-
pressed in the thymus or expressed there at very low levels.
Furthermore, there appears to be a requirement for a
threshold level of expression of the self-antigen in the pe-
riphery in order for this mechanism to have an impact. If
the level of antigen expression is too low it may simply be
ignored (40–42).
We showed previously that clone 4 CD8  cells under-
going activation in the pancreatic LNs of InsHA mice do
not receive the benefit of B7 costimulatory signals and ac-
quire only a limited proliferation potential. Furthermore,
they do not develop effector function before deletion (30).
This current study was undertaken to determine if provi-
sion of CD4  cells specific for HA could prevent tolerance
Figure 4. Blockade of B7 interaction inhibits accumulation and effec-
tor function of clone 4 CD8 T cells. (A) 3   106 CFSE-labeled, purified,
Thy1.1  clone 4 CD8  T cells were injected into InsHA recipients along
with anti-CD40 mAb or with 1.5   106 in vitro activated HNT CD4  T
cells. Half of the mice from the previous groups were treated with anti-
B7.1 plus anti-B7.2 mAbs and the rest were treated with a mixture of rat
and hamster IgG as isotype controls. On day 4 after transfer total numbers
of CD8  Thy1.1  cells in the pancreatic LNs of host mice were deter-
mined as in Fig. 2 B. Results represent data from six mice per group ana-
lyzed in two independent experiments. The line represent the number of
clone 4 CD8  T cells in mice that received clone 4 CD8  T cells with-
out anti-CD40 or HNT cells. (B) Production of IFN-  on day 4 after
transfer was determined as in Fig. 2 C.
Figure 5. Anti-CD40 treatment promotes enhanced migration of acti-
vated CD11c  cells to the pancreatic LNs of InsHA mice. Groups of
InsHA mice were treated with anti-CD40 or rat IgG isotype control poly-
clonal Ab. On day 4, cells from the pancreatic LN were analyzed by
FACS® for the expression of CD11c and B7.1 or B7.2 molecules. (A) To-
tal numbers of CD11c  cells in the pancreatic LNs. Data represent the
mean and standard deviation of seven mice analyzed in two independent
experiments. (B) Histograms represent the expression of B7 molecules
gating in CD11c  cells from the pancreatic LNs of representative treated
InsHA mice. The geometrical mean fluorescence intensity is indicated in
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induction of clone 4 CD8  cells in InsHA mice. Addition
of naive HA-specific HNT CD4  cells did increase some-
what the accumulation of activated clone 4 CD8  T cells,
suggesting some protection from deletion may occur, but
they could not induce effector function by the clone 4
CD8  cells. Only high numbers of in vitro activated HNT
cells were capable of transforming a tolerizing signal into a
signal resulting in the differentiation of naive clone 4
CD8  T cells into effector CTL.
One possible mechanism by which activated CD4  cells
may lead to development of effector CTL is by initiating  
cell damage and release of antigen. Although we do find
evidence of insulitis with activated HNT CD4  cells, we
do not think that it is an increase in antigen that results in
differentiation of CD8  cells into effectors. In a previous
study we showed that delivery of high levels of peptide an-
tigen to clone 4 CD8  cells in vivo resulted in strong pro-
liferation, yet did not lead to effector function (30). For this
reason, it is likely the development of effector function by
the CD8  cells is not simply due to greater antigen avail-
ability, but also reflects other proinflammatory signals pro-
vided to the APCs and CD8  cells as a result of the pres-
ence of the activated HNT CD4  cells.
In several previous studies CD4  T cell help has been
shown to prevent induction of CD8  T cell tolerance (32,
33). However, the nature of the APC was unknown. In a
recent study, the addition of naive OVA-specific CD4  T
cells was shown to hamper deletion of OVA-specific
CD8  T cells that occurs through cross-presentation of
self-antigen by DCs (34). In our results, it was necessary to
provide activated HA-specific CD4  cells in order to pre-
vent tolerance of the clone 4 CD8  cells. This difference
may simply reflect the fact that fewer T cells are activated
in the InsHA than the RIP-OVA model. OVA is expressed
at high levels in both the pancreas and kidneys in RIP-
OVA mice, which results in vigorous T cell activation (43).
There are at least two mechanisms by which CD4  cells
are able to prevent tolerance of CD8  cells. CD4  cells
provide IL-2, a cytokine that has multiple effects on CD8 
cells, including enhanced proliferation and the prevention
of anergy (23). In our experiments, IL-2 enhanced only
slightly the accumulation of clone 4 CD8 cells, but it did
not enhance proliferation or effector function. This may be
because the deletional mechanism of tolerance that occurs
in InsHA mice differs from the classical anergic phenotype
(30). The second pathway by which CD4  T cells may
prevent tolerance of CD8  T cells is by activating the APC
through interaction of the CD40L on CD4  T cells with
CD40 on the APC. It has been shown that activation of
antigen-presenting DCs through CD40 using an agonistic
anti-CD40 mAb can replace the requirement for CD4 help
in the development of certain CTL responses, including
those triggered by cross-presentation of antigen (15–17).
To probe the mechanism by which activated HNT CD4 
cells lead to development of clone 4 CD8  effectors, we
attempted to replace the HNT cells with anti-CD40. This
resulted in greatly enhanced proliferation and accumulation
of the clone 4 CD8  cells which corresponded with the re-
cruitment of greater numbers of antigen presenting DCs
expressing high levels of costimulatory molecules to the
pancreatic LNs. Clone 4 CD8   T cells proliferated exten-
sively, dividing  7 times and accumulating in the LNs.
However, unlike the clone 4 CD8  cells that became stim-
ulated in the presence of activated HNT CD4  cells, they
did not acquire effector function, and did not migrate into
the islets. This result was surprising in light of previous
studies that have reported the ability of anti-CD40 to aug-
ment induction of CTL that occurs through cross-presen-
tation of antigen by DCs (16, 17). However, in these pre-
vious studies effector cell function was not assessed in vivo
but rather after several days of in vitro stimulation of the in
vivo–primed CD8  cells. It is possible the in vitro activa-
tion conditions promoted effector cell function.
Numerous studies have shown that anti-CD40 activated
DCs can produce IL-12, a potent inducer of IFN-  pro-
duction. This was one reason we were so surprised to find
that anti-CD40 resulted in clonal expansion, but did not
result in expression of IFN-  by clone 4 CD8  cells.
However, in a recent study it was shown that although
DCs activated in vitro with anti-CD40 are able to secrete
IL-12, anti-CD40 was not sufficient to induce IL-12 pro-
duction in vivo (44). It was suggested this difference may
be due to additional activation signals received by DCs
during the process of their purification and culture. In a re-
cent report it has also been shown that anti-CD40 treat-
ment accelerates the deletion of tumor-specific CD8  T
cells in the absence of antigen priming without develop-
ment of effector function (45). Our results are consistent
with these findings.
We have found that the combination of anti-CD40 and
IL-12 promotes the generation of effector cells in vivo. Al-
though this method of effector cell generation appears less
efficient than with viral infection, we have observed that
the proportion of IFN- –producing cells varies with time
and dose of injection of these reagents (unpublished data).
For this reason, we believe the method of delivery may be
a major factor responsible for these differences. However, it
is likely that viral infection would result in production of
other proinflammatory cytokines and molecules that may
potentiate production of IFN-  by the activated CD8 
cells. Also, the fact that the combination of anti-CD40 and
IL-12 did not promote insulitis, which occurs with acti-
vated HNT CD4  cells, suggests that other proinflamma-
tory signals are required to sustain effector function.
We do not know if the generation of effector cells was
due to an effect by IL-12 on the CD8  cells or the APCs.
Not only does IL-12 activate DCs (46), but it also can act
directly on CD8  T cells, enhancing their clonal expan-
sion and differentiation into effector CTL in vitro (47). IL-
12 is also a powerful adjuvant in the development of CTL
responses in vivo (48). Furthermore, it has been shown
that IL-12 induces secretion of IFN-  by T cells and en-
hances cytolytic activity by CD8  T cells (48, 49). Nor-
mally, the major source of IL-12 in vivo is activated DCs.
We do not yet know if production of IL-12 is responsible
for clone 4 effector function as stimulated in the presence331 Hernández et al.
of activated HNT cells. Another cytokine that may be ex-
pressed under these conditions is IFN- . We have found
that administration of anti-CD40 and IFN-  also en-
hanced expression of IFN-  by clone 4 CD8  T cells (un-
published data). There may be a number of pathways that
can promote the development of CD8  effector function.
Our results demonstrate a clear distinction between the
signals involved in sustained proliferation and clonal ex-
pansion of CD8  T cells and the signals required for the
acquisition of effector function. As indicated by the effect
of anti-CD40, the combination of signal 1 (antigen) and
signal 2 (B7 costimulation) was sufficient to result in en-
hanced activation and accumulation of CD8 cells, how-
ever a third signal was required in order for these CD8 
cells to acquire effector function. It is generally accepted
that cells that receive signal 1 plus 2 are committed to a
differentiation program in which they will expand, under-
going multiple rounds of division, and become effectors.
Indeed, there have been several reports that have argued
that effector cell function occurred as a consequence of
successful division (50–53). However, our observation that
three signals, rather than two are required for production
of CTL supports the findings of Mescher and colleagues,
who proposed a similar three-signal model of CTL differ-
entiation based on studies performed using a cell-free sys-
tem of antigen presentation in vitro (47). Using antigen-
coated beads as stimulators of CD8  cells in vitro, they
determined that in addition to signals 1 and 2, a third signal
was required to induce CTL activity and that it may be
provided, in part, by IL-12. Here we have validated this
model in vivo and have extended this notion by assigning
a clear role for each of these signals in the differentiation
program of CD8  cells. Furthermore, we have correlated
these signals with situations in which there are differences
in the activation of the DCs. We have found that in re-
sponse to endogenous antigen cross-presented on APCs,
signal 1 alone promotes a limited proliferation potential
that leads to deletion (30). Signal 1 plus 2 (B7 costimula-
tion) leads to enhanced clonal expansion and accumulation
of CD8  cells, as observed in the presence of anti-CD40.
Signal 1 plus 2 plus 3 results in both clonal expansion, sur-
vival, and differentiation of the CD8  cells into effectors.
It is likely that activation of the innate immune system
would normally provide signal 3 in vivo.
Of interest, it has been reported that DCs that mature
in an IL-4 rich environment downregulate their expres-
sion of B7.1 and this prevents IFN-  production by
CD8  T cells (54). However, the observation that anti-
CD40 is not sufficient to promote effector function de-
spite successful upregulation of both B7.1 and B7.2, sug-
gests that other signals are involved in development of
effector function. It will be of interest to examine how the
conditions used for activation of the HNT CD4  cells
may alter the developmental program of the clone 4
CD8  cells in the InsHA model.
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